Spotlight Medical, a pioneering startup developing AI-driven prognosis tests to assist physicians in selecting the most effective treatment for cancer patients, announced that it has raised €6.2 million in a seed funding round. The investment was led by Kurma Partners and Heal Capital.’
This funding will enable Spotlight Medical to bring its first prognosis test to the clinic, marking a significant milestone in the commercialization of AI-based solutions for cancer treatment. By leveraging decades of patient treatment data, Spotlight Medical aims to ensure that no patient is over or undertreated, ultimately improving cancer outcomes.
Kurma Partners and Heal Capital recognize the transformative potential of Spotlight Medical’s technology. “We were impressed by the quality of the team and by their unique technology, quite different from what we usually see in the field of precision oncology,” said Benjamin Belot from Kurma Partners. Christian Lautner from Heal Capital added, “We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients’ lives.”
Also Read: Cognizant and Yseop announce plan to partner to scale medical writing through Generative AI
“We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment,” said Sylvain Berlemont, CEO of Spotlight Medical. “This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions.”
Founded in 2024 and backed by world-renowned cancer centers Institut Curie and Gustave Roussy, Spotlight Medical is dedicated to developing clinical tests that exploit the vast amount of information contained in patient data. By using advanced AI algorithms, the company aims to provide the first concrete AI-based solution for cancer patients, significantly enhancing the precision of cancer treatment.
Source: Businesswire
